Alerts on Ethos Technologies' Q2 results wrongly attributed to Atyr Pharma withdrawn

LIFE•2026-08-03

Advisory withdrawn

Alerts on Ethos Technologies' LIFE.O second-quarter results wrongly attributed to Atyr Pharma ATYR.O were inadvertently published and have been withdrawn.

For the correct set of alerts on Ethos' Q2 earnings, click nFWN4400U6.

Alerts on Ethos Technologies' Q2 results wrongly attributed to Atyr Pharma withdrawn

Advisory withdrawn

Related News

Globe Life Co-Chairman and CEO J. Matthew Darden sells 50,000 shares worth $9.13 million

Shentel CEO Edward H. McKay acquires 2,000 common shares for $24,280

Viemed Q2 FY26 net income falls 12.45% to USD 2.76 million; revenue rises 23.9% to USD 78.1 million

MasTec director Alex Spiro files initial beneficial ownership statement

Tonix publishes investor deck highlighting TONMYA fibromyalgia launch and pipeline updates